A Phase 1 interventional study of EC5026 oral tablet and Placebo oral tablet in Healthy Adults, sponsored by EicOsis Human Health Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by EicOsis Human Health Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to provide safety, tolerability, pharmacokinetics and food effects data of a single 8 mg oral dose of EC5026 in healthy subjects.
This is a single-center, double-blind, placebo-controlled, Phase 1a single dose study fed-fasted study evaluating the safety, tolerability, pharmacokinetics and food effects of a single 8 mg oral dose of EC5026 in healthy male and female subjects. EC5026 is an inhibitor of the soluble Epoxide Hydrolase (sEH) enzyme developed as a first-in-class analgesic for the treatment of pain. This study will help refine the dosing strategy for subsequent multiple-dose studies in healthy subjects and for future clinical trials in patients with pain.
sEH is an enzyme that is downstream in the cytochrome P450 (CYP) pathway of the arachidonic acid (AA) cascade. The sEH enzyme is responsible of metabolizing a class of epoxy-fatty acids known as epoxyeicosatrienoic acids (EETs), which are potent, naturally occurring analgesics. EETs are produced at high concentrations in areas of tissue damage and inflammation, but are rapidly metabolized by the sEH enzyme into inactive compounds. Effective inhibition of sEH activity prolongs the ability of EETs to exert their analgesic activity.
EicOsis Human Health Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each subject must meet all of the following criteria to be enrolled in this study:
Exclusion Criteria:
Subjects meeting any of the following criteria will be excluded from the study:
Subjects who have used (within 30 days of randomization) or plan on using any of the following during the duration of the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 8 mg oral dose of EC5026
Drug: EC5026 oral tablet
Single dose of matching oral placebo
Other: Placebo oral tablet
12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences: * Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or * Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2.
6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions. Note: Subjects assigned to the placebo arm will not return for a second Dosing Period.
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE) [Safety and Tolerability]
All AEs reported or observed during the study will be recorded on the electronic case report forms (eCRF). Information to be collected includes drug treatment, type of event, time of onset, dosage, investigator-specified assessment of severity and relationship to study drug, time of resolution of the event, seriousness, any required treatment or evaluations, and outcome. Any AEs resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or progression of disease states must also be reported. All AEs will be followed until they are resolved, stable, or judged by the investigator to be not clinically significant. The Medical Dictionary for Regulatory Activities will be used to code all AEs.
Time frame: 77 days
Area under the plasma concentration versus time curve (AUC) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Maximum observed plasma concentration (Cmax) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Time to maximum observed plasma concentration (Tmax) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Terminal elimination rate constant in plasma (Kel) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Terminal phase half-life in plasma (t1/2) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Apparent total body clearance (CL/F) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Apparent volume of distribution based on the terminal elimination rate constant in plasma (Vz/F) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Renal clearance (CLR) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Amount of drug excreted unchanged in urine (Ae) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Amount of drug excreted within the time interval t1 to t2 (Ae(t1-t2)) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Fraction of eliminated dose in urine (Fe%) in response to a single 8mg EC5026 oral tablet [Plasma Pharmacokinetics].
Standard noncompartmental methods will be used. The effects on this parameter of a effect of a high-fat, high-calorie meal will be evaluated in comparison to fasted conditions.
Time frame: 14 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in May 2021, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EC5026
EicOsis Human Health Inc.